Restart Life Sciences Corp. (NMLSF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Restart Life Sciences Corp. (NMLSF) trades at $0.04. Restart Life Sciences Corp. is a biotechnology company focused on the research and development of psilocybin-based therapies. Market cap: $1.28M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for NMLSF: NMLSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NMLSF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NMLSF: 1/1 perspectives are bearish.
Restart Life Sciences Corp. (NMLSF) Healthcare & Pipeline Overview
Restart Life Sciences Corp., a biotechnology firm, researches and develops psilocybin for neuroinflammatory disorders. Based in Vancouver, Canada, the company offers therapy and diagnostics, competing within the biotechnology sector with a focus on innovative treatments and diagnostic tools, while facing the inherent risks of drug development and regulatory approvals.
What Is the Investment Thesis for NMLSF?
Restart Life Sciences Corp. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on psilocybin-based therapies for neuroinflammatory disorders positions it in a niche market with potential for significant growth, contingent on successful clinical trials and regulatory approvals. Key value drivers include the advancement of its research pipeline, strategic partnerships, and potential market exclusivity through patents. However, the company faces substantial risks, including regulatory hurdles, clinical trial failures, and competition from established pharmaceutical companies. The company's negative P/E ratio of -1.36 reflects its current lack of profitability, highlighting the speculative nature of the investment. Investors should carefully consider the company's financial position, research progress, and the evolving regulatory landscape surrounding psilocybin before making investment decisions.
Based on FMP financials and quantitative analysis
NMLSF Key Highlights
- Focus on psilocybin research and development for neuroinflammatory disorders.
- Offers therapy and diagnostics for neuroinflammatory disorders.
- Headquartered in Vancouver, Canada, indicating a North American presence.
- Founded in 2004, suggesting over two decades of operational history.
- Negative P/E ratio of -1.36, reflecting current lack of profitability.
Who Are NMLSF's Competitors?
NMLSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADXS Ayala Pharmaceuticals, Inc. | $0.60 | +0.00% | $25.71M | 43 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | $2.42B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $3.97 | +2.32% | $374.45M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| SLGL Sol-Gel Technologies Ltd. | $73.44 | -2.47% | $206.36M | 68 |
| CELU Celularity Inc. | $0.73 | +0.44% | $17.56M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NMLSF's Key Strengths?
- Focus on innovative psilocybin-based therapies.
- Potential for breakthrough treatments for neuroinflammatory disorders.
- Experienced leadership in biotechnology research and development.
- Strategic location in Vancouver, Canada, a hub for biotech innovation.
What Are NMLSF's Weaknesses?
- Limited financial resources and reliance on external funding.
- High dependence on successful clinical trials and regulatory approvals.
- Small market capitalization and limited trading volume.
- Negative P/E ratio indicating current lack of profitability.
What Could Drive NMLSF Stock Higher?
- Announcement of results from ongoing preclinical studies of psilocybin-based therapies.
- Potential partnerships with pharmaceutical companies for collaborative research and development.
- Advancements in regulatory approvals for psilocybin-based therapies in key markets.
- Increasing acceptance and awareness of psychedelic therapies in the medical community.
- Expansion of research into new therapeutic applications of psilocybin.
What Are the Key Risks for NMLSF?
- Regulatory hurdles and evolving policies on psilocybin.
- Risk of clinical trial failures and adverse side effects.
- Competition from established pharmaceutical companies.
- Limited financial resources and reliance on external funding.
- Small market capitalization and limited trading volume.
What Are the Growth Opportunities for NMLSF?
- Expansion into new therapeutic areas: Restart Life Sciences Corp. can explore the application of psilocybin-based therapies for other neurological and psychiatric disorders beyond neuroinflammation. This could involve research into conditions such as depression, anxiety, and PTSD, significantly expanding the company's target market and revenue potential. The market for mental health treatments is substantial and growing, offering a significant opportunity for Restart Life Sciences to diversify its product pipeline and address unmet medical needs. This expansion would require further research, clinical trials, and regulatory approvals, but could yield substantial long-term growth.
- Strategic partnerships and collaborations: Collaborating with academic institutions, research organizations, and pharmaceutical companies can accelerate the development and commercialization of Restart Life Sciences' therapies. Partnerships can provide access to funding, expertise, and distribution networks, enhancing the company's capabilities and reach. For example, partnering with a major pharmaceutical company could facilitate larger-scale clinical trials and streamline the regulatory approval process. These collaborations can also reduce the financial burden on Restart Life Sciences, allowing it to focus on its core research and development activities. Successful partnerships could significantly enhance the company's credibility and market position.
- Geographic expansion into new markets: Restart Life Sciences can expand its operations into new geographic markets, particularly in regions where regulations surrounding psilocybin are becoming more favorable. This could involve establishing research facilities, conducting clinical trials, and seeking regulatory approvals in countries with progressive policies on psychedelic therapies. Expanding into markets such as Europe and Australia could provide access to new patient populations and revenue streams. However, this expansion would require careful consideration of local regulations, cultural factors, and market dynamics. A well-executed geographic expansion strategy could significantly increase the company's global presence and market share.
- Development of novel drug delivery systems: Investing in the development of innovative drug delivery systems for psilocybin can enhance the efficacy and patient experience of Restart Life Sciences' therapies. This could involve exploring methods such as sublingual tablets, nasal sprays, or transdermal patches, which offer improved bioavailability and ease of administration compared to traditional oral capsules. Developing proprietary drug delivery technologies can also provide a competitive advantage and protect the company's intellectual property. The market for advanced drug delivery systems is growing, driven by the demand for more convenient and effective treatments. Successful development and implementation of these systems could significantly enhance the value of Restart Life Sciences' product pipeline.
- Securing intellectual property protection: Obtaining patents and other forms of intellectual property protection for its psilocybin-based therapies is crucial for maintaining a competitive advantage and preventing competitors from replicating its innovations. This involves filing patent applications for novel formulations, drug delivery systems, and therapeutic applications of psilocybin. Strong intellectual property protection can provide market exclusivity and allow Restart Life Sciences to capture a larger share of the market. The process of obtaining and enforcing patents can be complex and costly, but it is essential for protecting the company's investments in research and development. A robust intellectual property portfolio can also attract potential partners and investors.
What Opportunities Does NMLSF Have?
- Expansion into new therapeutic areas and geographic markets.
- Strategic partnerships and collaborations with pharmaceutical companies.
- Development of novel drug delivery systems for psilocybin.
- Increasing acceptance and legalization of psychedelic therapies.
What Threats Does NMLSF Face?
- Regulatory hurdles and evolving policies on psilocybin.
- Competition from established pharmaceutical companies.
- Risk of clinical trial failures and adverse side effects.
- Potential for generic competition and patent infringement.
What Are NMLSF's Competitive Advantages?
- Proprietary research and development of psilocybin-based therapies.
- Intellectual property protection through patents and trademarks.
- Expertise in the treatment of neuroinflammatory disorders.
- Potential for market exclusivity through regulatory approvals.
What Does NMLSF Do?
Restart Life Sciences Corp., established on October 27, 2004, operates as a biotechnology company headquartered in Vancouver, Canada. The company is dedicated to the research and development of psilocybin, a naturally occurring psychoactive compound found in certain species of mushrooms, for therapeutic applications. Restart Life Sciences focuses on creating therapies and diagnostics for neuroinflammatory disorders, addressing conditions that affect the nervous system and cause inflammation. The company's activities encompass preclinical research, clinical trials, and the potential development of pharmaceutical products based on psilocybin. Restart Life Sciences aims to innovate in the treatment of neuroinflammatory conditions, which can include diseases such as multiple sclerosis, Alzheimer's disease, and other neurological disorders. By exploring the therapeutic potential of psilocybin, the company seeks to provide new treatment options for patients with limited alternatives. The company operates primarily in the biotechnology sector, focusing on novel drug development and diagnostic solutions.
What Products and Services Does NMLSF Offer?
- Researches and develops psilocybin-based therapies.
- Focuses on treatments for neuroinflammatory disorders.
- Offers diagnostic solutions for neuroinflammatory conditions.
- Conducts preclinical research and clinical trials.
- Aims to develop pharmaceutical products based on psilocybin.
- Innovates in the treatment of neurological disorders.
- Explores the therapeutic potential of psychedelic compounds.
How Does NMLSF Make Money?
- Research and development of psilocybin-based therapies.
- Seeking partnerships and collaborations for funding and expertise.
- Commercialization of approved therapies and diagnostic tools.
- Securing intellectual property protection for its innovations.
What Industry Does NMLSF Operate In?
Restart Life Sciences Corp. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory scrutiny, and significant growth potential. The market for neuroinflammatory disorder treatments is expanding, driven by an aging population and increased prevalence of neurological diseases. Competition includes both established pharmaceutical companies and emerging biotech firms, all vying for market share with innovative therapies. The company's focus on psilocybin places it in a specialized segment, potentially offering a unique value proposition but also facing specific regulatory challenges related to the use of psychedelic compounds.
Who Are NMLSF's Key Customers?
- Patients with neuroinflammatory disorders.
- Healthcare providers and medical professionals.
- Research institutions and academic partners.
- Pharmaceutical companies for potential collaborations.
NMLSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
NMLSF Latest News
No recent news available for NMLSF.
NMLSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NMLSF.
Price Targets
Wall Street price target analysis for NMLSF.
NMLSF MoonshotScore
What does this score mean?
The MoonshotScore rates NMLSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Steve Loutskou
CEO
Steve Loutskou serves as the CEO of Restart Life Sciences Corp. His background includes experience in the biotechnology sector, with a focus on early-stage drug development and corporate strategy. He has been involved in various aspects of the biotechnology industry, including fundraising, clinical trial management, and regulatory affairs. Loutskou's expertise lies in guiding companies through the complex process of bringing novel therapies to market, with a particular emphasis on innovative treatments for neurological disorders. His leadership aims to drive Restart Life Sciences forward in its research and development efforts.
Track Record: Under Steve Loutskou's leadership, Restart Life Sciences Corp. has focused on advancing its research pipeline of psilocybin-based therapies. Key milestones include initiating preclinical studies and securing partnerships to support research efforts. Loutskou has been instrumental in navigating the regulatory landscape surrounding psychedelic therapies and positioning the company for future growth. His strategic decisions have focused on building a strong foundation for clinical development and commercialization.
NMLSF OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that Restart Life Sciences Corp. may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, which increases investment risk. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing requirements, resulting in less transparency and potentially greater volatility. Investors should exercise significant caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- Limited regulatory oversight and investor protection.
- Difficulty in obtaining reliable information and conducting due diligence.
- Verify the company's registration and legal standing.
- Thoroughly review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a qualified financial advisor before investing.
- Check for any regulatory actions or legal disputes involving the company.
- Presence of a professional website and investor relations materials.
- Independent audits of financial statements (if available).
- Positive media coverage and industry recognition.
- Strategic partnerships with reputable organizations.
- Active engagement with shareholders and the investment community.
Common Questions About NMLSF (Healthcare)
What does Restart Life Sciences Corp. do?
Restart Life Sciences Corp. is a biotechnology company focused on the research, development, and potential commercialization of psilocybin-based therapies. The company aims to address neuroinflammatory disorders by innovating in treatment and diagnostic solutions. Their core activities include preclinical research, clinical trials, and the pursuit of regulatory approvals for their therapeutic candidates. By exploring the therapeutic potential of psilocybin, Restart Life Sciences seeks to provide new treatment options for patients with limited alternatives, positioning itself as a key player in the emerging field of psychedelic medicine.
What do analysts say about NMLSF stock?
As of 2026-03-16, formal analyst coverage of Restart Life Sciences Corp. (NMLSF) appears limited, likely due to its OTC listing and small market capitalization. The company's valuation is challenging to assess given its current lack of profitability, reflected in its negative P/E ratio. Growth considerations center on the successful advancement of its research pipeline and the evolving regulatory landscape for psilocybin-based therapies. Investors should conduct thorough due diligence and consider the speculative nature of the investment before making any decisions.
What are the main risks for NMLSF?
Restart Life Sciences Corp. faces several key risks inherent to the biotechnology industry and its specific focus on psilocybin. Regulatory hurdles and evolving policies surrounding psychedelic substances pose a significant challenge. Clinical trial failures and potential adverse side effects could derail the development of its therapies. Competition from established pharmaceutical companies with greater resources is another major risk. Additionally, the company's limited financial resources and small market capitalization make it vulnerable to market volatility and funding challenges. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for NMLSF?
Evaluate NMLSF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does NMLSF data refresh on this page?
NMLSF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NMLSF's recent stock price performance?
Restart Life Sciences Corp. (NMLSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative psilocybin-based therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NMLSF overvalued or undervalued right now?
Valuing Restart Life Sciences Corp. (NMLSF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NMLSF?
Before investing in Restart Life Sciences Corp. (NMLSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage and financial data available for NMLSF.
- OTC market investments carry higher risk than exchange-listed stocks.
- Psilocybin-based therapies are subject to regulatory uncertainty.